<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301639</url>
  </required_header>
  <id_info>
    <org_study_id>2004-p-002189</org_study_id>
    <nct_id>NCT00301639</nct_id>
  </id_info>
  <brief_title>A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults</brief_title>
  <official_title>A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McNeil Consumer &amp; Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The specific aim of this study is to document the pharmacokinetics of dopamine transporter&#xD;
      DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as&#xD;
      the ligand. We hypothesize that CNS DAT occupancy of OROS MPH will be greater than that of&#xD;
      Metadate CD at 10 hours after administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OROS-MPH's pharmacokinetic profile uses an increasing delivery of MPH over the day (ascending&#xD;
      pharmacokinetic curve). It was designed to replace IR-MPH TID treatment. Another new&#xD;
      long-acting formulation is Metadate CD. Metadate CD consists of capsules with two types of&#xD;
      beads. It was designed to replace IR-MPH BID treatment. The main target of MPH in the brain&#xD;
      is the dopamine transporter (DAT). We have an exquisitely sensitive methodology to measure&#xD;
      DAT occupancy using C-11 Altropane and Positron Emission Tomography (PET). The time course of&#xD;
      decay of the C-11 Altropane permits repeated imaging, thus allowing documentation of the&#xD;
      pharmacokinetics of DAT receptor occupancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane. Objective measures also provided by d and l ritalinic acid and methylphenidate levels at pre-dose, hr 9, 10 and 11.</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS methylphenidate hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent to participate in the study.&#xD;
&#xD;
          2. Age: 18 - 55&#xD;
&#xD;
          3. If female, non-pregnant, non-nursing, using an adequate form of birth control or a&#xD;
             negative serum pregnancy test.&#xD;
&#xD;
          4. Supine and standing blood pressure within the range 110/60 to 150/90 mmHg.&#xD;
&#xD;
          5. Heart rate, after resting for 5 minutes, within the range 46-90 beats/min.&#xD;
&#xD;
          6. Subjects who are within 20% of the ideal weight for height.&#xD;
&#xD;
          7. Right handed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of any psychotic disorder, bipolar disorder, severe depression, severe&#xD;
             anxiety, or Autism. Subjects with mild mood, oppositional, conduct, and anxiety&#xD;
             disorders may be permitted to participate if considered appropriate by the&#xD;
             investigator.&#xD;
&#xD;
          2. Scores of Baseline Scales:&#xD;
&#xD;
             Hamilton Depression Scale &gt; 17 (out of a possible 67 on the 21-item scale) (Hamilton&#xD;
             1960) Beck Depression Inventory &gt; 19 (out of a possible 63 on the 21-item scale) (Beck&#xD;
             et al 1961) Hamilton Anxiety Scale &gt; 21 (out of a possible 56 on the 14-item scale)&#xD;
             (Hamilton 1959)&#xD;
&#xD;
          3. Tics or Tourette's Syndrome.&#xD;
&#xD;
          4. Diagnosis of ADHD&#xD;
&#xD;
          5. History of head trauma with loss of consciousness, organic brain disorders, seizures,&#xD;
             or neurosurgical intervention.&#xD;
&#xD;
          6. Any clinically significant chronic medical condition, in the judgment of the&#xD;
             investigator.&#xD;
&#xD;
          7. Mental impairment as evidenced by an I.Q. &lt;75.&#xD;
&#xD;
          8. Exposure to dopamine receptor antagonists within the previous three (3) months.&#xD;
&#xD;
          9. Exposure to radiopharmaceuticals within four (4) weeks prior to PET scan.&#xD;
&#xD;
         10. Subjects receiving psychotropic medication.&#xD;
&#xD;
         11. Any clinically significant abnormality in the screening laboratory tests, vital signs,&#xD;
             or 12-lead ECG, outside of normal limits.&#xD;
&#xD;
         12. Any woman of childbearing potential who is seeking to become pregnant or suspects that&#xD;
             she may be pregnant.&#xD;
&#xD;
         13. Subjects with a known recent history (within the past six (6) months) of illicit drug&#xD;
             or alcohol dependence.&#xD;
&#xD;
         14. Subjects diagnosed with glaucoma.&#xD;
&#xD;
         15. Subjects at risk for MPH toxicity (e.g. individuals with arrhythmias, coronary artery&#xD;
             disease, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Spencer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas J. Spencer, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

